|Application ||WB, IF, ICC, E|
|Other Accession||AAI19685, 111601409|
|Calculated MW||48544 Da|
|Application Notes||SCRN3 antibody can be used for detection of SCRN3 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunocytochemistry starting at 20 µg/mL. For immunofluorescence start at 20 µg/mL.|
|Reconstitution & Storage||SCRN3 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.|
|Precautions||SCRN3 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
SCRN3 Antibody: SCRN3 is a member of the secernin family of proteins which includes the homologous SCRN1, a protein that was first identified as being involved in the regulation of exocytosis from peritoneal mast cells. Little is known of SCRN3, but studies have shown that SCRN1 may possess epitopes that function as tumor-associated antigens in gastric cancers and increased SCRN1 expression in patients with colorectal cancer correlated with poor prognosis, suggesting that SCRN3 may also be involved in protein secretion or the regulation of cell growth.
Way G, Morrice N, Smythe C, et al. Purification and identification of Secernin, a novel cytosolic protein that regulates exocytosis in mast cells. Mol. Biol. Cell2002; 13:3344-54.
Suda T, Tsunoda T, Uchida N, et al. Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci.2006; 97:411-9.
Miyoshi N, Ishii H, Mimori K, et al. SCRN1 is a novel marker for prognosis in colorectal cancer. J. Surg. Oncol.2010; 101:156-9.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.